Global pharmaceutical manufacturers are accelerating capital commitments to sterile fill-finish infrastructure. Unprecedented sustained demand for GLP-1 receptor agonists has exposed structural capacity limitations across the global biologic manufacturing supply network.
Contract Manufacturing Realignment
Major drugmakers are increasingly acquiring specialized production sites outright rather than relying on third-party contract development organizations, securing direct control over high-volume fill-finish lines.